Conference item icon

Conference item

Development of lung and muscle protein factories to deliver therapeutic monoclonal antibodies

Abstract:
Recombinant therapeutic proteins, of which monoclonal antibodies (mAbs) represent the largest market, are used to treat diseases including cancer, blood and immune disorders. The cost and complexity of large-scale production and purification of mAbs translates to high cost of therapy. We hypothesise that our rSIV.F/HN lentiviral lung gene delivery platform, currently undergoing preclinical evaluation for cystic fibrosis gene therapy, could be used to establish protein factories within patients' lungs.
Publication status:
Published
Peer review status:
Peer reviewed

Actions


Access Document


Files:
Publisher copy:
10.1089/hum.2016.29027.abstracts

Authors


More by this author
Institution:
University of Oxford
Division:
MSD
Department:
RDM
Role:
Author
More by this author
Institution:
University of Oxford
Division:
MSD
Department:
RDM
Role:
Author
More by this author
Institution:
University of Oxford
Division:
MSD
Department:
RDM
Sub department:
RDM Clinical Laboratory Sciences
Role:
Author
More by this author
Institution:
University of Oxford
Division:
MSD
Department:
RDM
Sub department:
RDM Clinical Laboratory Sciences
Role:
Author
More by this author
Institution:
University of Oxford
Oxford college:
University College
Role:
Author
Publisher:
Mary Ann Liebert Inc Publisher's website
Journal:
13th Annual Meeting of the British Society for Gene and Cell Therapy (BSGCT 2016) Journal website
Host title:
13th Annual Meeting of the British Society for Gene and Cell Therapy (BSGCT 2016)
Publication date:
2016-06-01
DOI:
ISSN:
1043-0342
Source identifiers:
720845
Pubs id:
pubs:720845
UUID:
uuid:66a643d1-7c76-4447-a7b5-8311b6e93d03
Local pid:
pubs:720845
Deposit date:
2017-09-08

Terms of use


Views and Downloads






If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP